Adjutec applies for phase I start

Norwegian AdjuTec Pharma prepares for clinical trials with its concept for battling antimicrobial resistance.
The company recently raised 16 MNOK and sent a clinical trial application to the swedish regulatory autorities, aming to start phase I this summer. BioStock contacted CEO Bjørn Klem to get an update.